Skip to main content

Charles Gersbach

John W. Strohbehn Distinguished Professor of Biomedical Engineering
Biomedical Engineering
Box 90281, 136 Hudson Hall, Durham, NC 27708
2123 CIEMAS, Durham, NC 27708

Current Appointments & Affiliations


John W. Strohbehn Distinguished Professor of Biomedical Engineering · 2021 - Present Biomedical Engineering, Pratt School of Engineering
Professor of Biomedical Engineering · 2021 - Present Biomedical Engineering, Pratt School of Engineering
Associate Professor of Surgery · 2019 - Present Surgery, Surgical Sciences, Surgery
Associate Professor in Orthopaedic Surgery · 2015 - Present Orthopaedic Surgery, Clinical Science Departments
Associate Professor in Cell Biology · 2020 - Present Cell Biology, Basic Science Departments
Professor in Molecular Genetics and Microbiology · 2025 - Present Molecular Genetics and Microbiology, Basic Science Departments
Member of the Duke Cancer Institute · 2013 - Present Duke Cancer Institute, Institutes and Centers
Associate of the Duke Initiative for Science & Society · 2017 - Present Duke Science & Society, University Initiatives & Academic Support Units
Affiliate of the Duke Regeneration Center · 2021 - Present Duke Regeneration Center, Basic Science Departments

In the News


Published February 13, 2025
Activating Complex Regions of the Genome to Treat Rare Diseases
Published November 8, 2024
Genomic Medicine, Beyond CRISPR
Published October 2, 2024
Duke 100 Trailblazer: Charles Gersbach

View All News

Recent Publications


The IGVF catalog-from genetic variation to function.

Journal Article Nucleic Acids Res · January 6, 2026 Genomic variation between individuals is essential for understanding how differences in the genome sequence affect molecular and cellular processes. The Impact of Genomic Variation on Function (IGVF) Consortium aims to uncover the relationships among genom ... Full text Link to item Cite

Monitoring biological effects of somatic cell genome editing.

Journal Article Nature reviews. Genetics · January 2026 CRISPR-based genome editing therapeutics are entering the clinic, offering transformative potential but also presenting potential risks. Preclinical-to-clinical toolkits are needed to assess the safety and efficacy of these new therapies and accelerate pro ... Full text Cite
View All Publications

Recent Grants


Pharmacological Sciences Training Program

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030

Chromatin dysregulation in neurodevelopmental disorders

ResearchCollaborator · Awarded by National Institute of Neurological Disorders and Stroke · 2024 - 2029

Epigenetic Programming of T Cells for Enhanced Cellular Immunotherapy

ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2024 - 2029

View All Grants

Education, Training & Certifications


Georgia Institute of Technology · 2006 Ph.D.
Georgia Institute of Technology · 2001 B.S.